Product Description
It is hypothesized that steady-state levels of KB001-A in CF subjects with airway Pa infection will be safe and well-tolerated, and will increase the time-to-need for antibiotic treatment (IV, inhaled, or oral) for worsening of respiratory tract signs and symptoms compared with placebo.
Mechanisms of Action: PcrV Antagonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Humanigen, Inc.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Cystic Fibrosis|Pseudomonas Infections|Pneumonia, Ventilator-Associated
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01695343 |
KB001-A | P2 |
Completed |
Cystic Fibrosis |
2014-11-01 |
2019-03-19 |
Treatments |
|
NCT00691587 |
KB001-04 | P2 |
Completed |
Pneumonia, Ventilator-Associated|Pseudomonas Infections |
2009-03-01 |
2019-03-22 |
Treatments |
|
NCT00638365 |
KB001-03 | P2 |
Completed |
Cystic Fibrosis|Pseudomonas Infections |
2009-03-01 |
2019-03-18 |
Treatments |
|
2007-006764-29 |
2007-006764-29 | P2 |
Active, not recruiting |
Unknown |
2009-02-25 |
2022-03-12 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/09/2021 |
News Article |
Keystone Bio Recognizes the Big "GAIN" from Cortexyme's Trial Results |
|
07/29/2021 |
News Article |
Keystone Bio Advances a More Complete Explanation of Porphyromonas Gingivalis Toxic Virulence Factors as Major Driver of Sporadic Alzheimer's and Chronic Inflammation |